WO2003060118A1 - Proteine fer-soufre, complexe proteine-fad, transporteur d'electrons, et procede de mesure de l'inhibition de l'activite de ferredoxine - Google Patents

Proteine fer-soufre, complexe proteine-fad, transporteur d'electrons, et procede de mesure de l'inhibition de l'activite de ferredoxine Download PDF

Info

Publication number
WO2003060118A1
WO2003060118A1 PCT/JP2003/000087 JP0300087W WO03060118A1 WO 2003060118 A1 WO2003060118 A1 WO 2003060118A1 JP 0300087 W JP0300087 W JP 0300087W WO 03060118 A1 WO03060118 A1 WO 03060118A1
Authority
WO
WIPO (PCT)
Prior art keywords
iron
protein
sulfur
activity
ferredotoxin
Prior art date
Application number
PCT/JP2003/000087
Other languages
English (en)
Japanese (ja)
Inventor
Toshiharu Hase
Yoko Ariga
Masami Kusunoki
Genji Kurisu
Toshihiro Horii
Dan Sato
Ken Okada
Original Assignee
Osaka Industrial Promotion Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Industrial Promotion Organization filed Critical Osaka Industrial Promotion Organization
Priority to AU2003201846A priority Critical patent/AU2003201846A1/en
Publication of WO2003060118A1 publication Critical patent/WO2003060118A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne: une protéine fer-soufre qui se prête au criblage de médicament pour les maladies induites par un protozoaire du genre Apicomplexan et à l'évaluation de son activité; un transporteur d'électrons; un procédé de mesure de l'inhibition de l'activité de transport d'électrons par la ferredoxine issue du protozoaire, etc. Précisément, l'invention concerne des protéines fer-soufre qui se constituent sensiblement dans un protozoaire du genre Apicomplexan, et qui ont l'une des deux caractéristiques suivantes: (a) protéine fer-soufre à groupe fer-soufre coordonné dans la protéine, comprenant la séquence d'acides aminés représentée par SEQ ID N°:1; et (b) protéine fer-soufre à groupe fer-soufre coordonné dans la protéine, comprenant une séquence d'acides aminés dérivée de la séquence d'acides aminés représentée par SEQ ID N°:1, par suppression, substitution ou adjonction d'un ou plusieurs acides aminés, et ayant une activité de transport d'électrons.
PCT/JP2003/000087 2002-01-09 2003-01-08 Proteine fer-soufre, complexe proteine-fad, transporteur d'electrons, et procede de mesure de l'inhibition de l'activite de ferredoxine WO2003060118A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003201846A AU2003201846A1 (en) 2002-01-09 2003-01-08 Iron-sulfur protein, protein-fad complex, electron transporter and method of measuring the inhibition of ferredotoxin activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-2567 2002-01-09
JP2002002567A JP2005295801A (ja) 2002-01-09 2002-01-09 電子伝達剤、ｄｎａ、アピコンプレキサン類原虫のアピコプラスト由来フェレドキシンの製造方法、フェレドキシン結晶、及び、フェレドキシン活性阻害の測定方法

Publications (1)

Publication Number Publication Date
WO2003060118A1 true WO2003060118A1 (fr) 2003-07-24

Family

ID=19190759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/000087 WO2003060118A1 (fr) 2002-01-09 2003-01-08 Proteine fer-soufre, complexe proteine-fad, transporteur d'electrons, et procede de mesure de l'inhibition de l'activite de ferredoxine

Country Status (3)

Country Link
JP (1) JP2005295801A (fr)
AU (1) AU2003201846A1 (fr)
WO (1) WO2003060118A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105238733A (zh) * 2015-11-24 2016-01-13 山东大学 一株高效表达2[4Fe4S]铁氧还蛋白的重组大肠杆菌及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRELLIER P. ET AL.: "Antiplasmodial activity of nitroaromatic and quinoidal compounds: redox potential vs. inhibition of erythrocyte glutathione reductase", ARCH. BIOCHEM. BIOPHYS., vol. 393, no. 2, 15 September 2001 (2001-09-15), pages 199 - 206, XP002967097 *
MORALES R. ET AL.: "Refined X-ray structures of the oxidized, at 1.3 A and reduced, at 1.17 A, (2Fe-2S) ferredoxin from the cyanobacterium anabaena PCC7119 show redox-linked conformational changes", BIOCHEMISTRY, vol. 38, no. 48, 30 November 1999 (1999-11-30), pages 15764 - 15773, XP002967095 *
SERRE L. ET AL.: "X-ray structure of the ferredoxin: NADP+ reductase from the cyanobacterium anabaena PCC7119 at 1.8 A resolution and crystallographic studies of NADP+ binding at 2.25 A resolution", J. MOL. BIOL., vol. 263, no. 1, 18 October 1996 (1996-10-18), pages 20 - 39, XP002967096 *
VOLLMER M. ET AL.: "Apicomplexan parasites possess distinct nuclear-encoded, but apicoplast-localized, plant-type ferredoxin-NADP+ reductase and ferredoxin", J. BIOL. CHEM., vol. 276, no. 8, 23 February 2001 (2001-02-23), pages 5483 - 5490, XP002967094 *

Also Published As

Publication number Publication date
AU2003201846A1 (en) 2003-07-30
JP2005295801A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
EP1801206A4 (fr) Methode de synthese de la l-arginine, de la l-ornithine, ou de la l-citrulline
IL210454A (en) Antibody against a new ligand of cytokine 17zcytor
IL175319A (en) Phosphorus-related protein, preparations containing @ the same L @ use @ it @ and method @ to identify it
WO2007029262A3 (fr) Compositions et methodes d'utilisation de ces dernieres en vue de detecter des virus
AU7653100A (en) A minimal tau peptide for the nucleation of paired helical filaments
EP1548107A4 (fr) Chromoproteine et fluoroproteines
IL152406A0 (en) Anti-freeze proteins, their production and use
WO2003027149A1 (fr) Anticorps et utilisation de ce dernier
WO2007058267A8 (fr) Proteine innovante et gene codant pour la proteine
WO2004099240B1 (fr) Peptides et certains de leurs melanges convenant a la detection du coronavirus associe au syndrome respiratoire aigu severe (sras)
Jost et al. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma
WO2003060118A1 (fr) Proteine fer-soufre, complexe proteine-fad, transporteur d'electrons, et procede de mesure de l'inhibition de l'activite de ferredoxine
AU2001289034A1 (en) Novel pdes and uses thereof
WO2002102847A1 (fr) Nouveau ligand et son adn
MY150639A (en) T cell adhesion molecule and antibody thereto
CA2367468A1 (fr) Gene de la polyarthrite rhumatoide et procede permettant de diagnostiquer la polyarthrite rhumatoide
WO2003060516A1 (fr) Methode de criblage
WO2002008424A1 (fr) Genes abca2 humain et de rat
WO2002072753A3 (fr) Peptides de thymidylate synthase se fixant a l'arnm de la thymidylate synthase
WO2003087352A3 (fr) Polypeptides d'enolase et structures correspondantes
AU2003240449A1 (en) Association of edg5 polymorphism v286a with type ii diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof
AU2003242574A1 (en) Inhibitors of proteins from the rho-gef family
WO2004013167A3 (fr) Nouveaux polypeptides purifies issus d'enterococcus faecalis
AU2003258723A1 (en) Use of the protein maba (fabg1) of less thanigreater thanmycobacterium tuberculosisless than/igreater than for designing and screening antibiotics
US20080108547A1 (en) Protease Inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP